BVNKF:OTCMKTS
Bavarian Nordic A/S
36,06 US$
0,00%
(0,00) 1D
8 tet, 3:46:25 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për BVNKF...
Kapitalizimi i tregut
2,80 mld
Vëllimi mesatar
14,00
Vëllimi
0,00
Maksimumi 52-javor
37,22 US$
Minimumi 52-javor
27,69 US$
Beta
1,46
Aksionet në qarkullim
79,26 mln
Numri i punonjësve
2 mijë
Kapitalizimi i tregut
2,80 mld
Vëllimi mesatar
14,00
Vëllimi
0,00
Maksimumi 52-javor
37,22 US$
Minimumi 52-javor
27,69 US$
Beta
1,46
Aksionet në qarkullim
79,26 mln
Numri i punonjësve
2 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Simply Wall Street
·
1 orë më parë
Palo Alto Networks (PANW) Becomes Founding Partner In Critical Infrastructure Defense Program
巴士的報
·
50 minuta më parë
Oracle NetSuite Announces Launch of AI-first QuickStart: NYSE Content Update
24/7 Wall St.
·
53 minuta më parë
Michael Burry Says Stocks Could Peak Within 9 Months — and He’s Betting Against the Nasdaq and Chip Stocks
Profili
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Rreth Bavarian Nordic A/S
Drejtori ekzekutivPaul Chaplin
Punonjësit1,91 mijë
Themeluar më1 korr 1992
Selia-
Sektori-
Uebsajtibavarian-nordic.com